Thank you for your interest in contributing to the consultation process at Canada’s Drug Agency (CDA-AMC) — we benefit from your valuable input. The purpose of this consultation is to gather feedback on a draft of our methods guide. If you have questions about the document or consultation process, please send them to us via [email protected]
How to Participate
To provide comments, please complete this feedback form. The deadline for feedback is January 28, 2025.
- Feedback should be presented clearly and succinctly in point form, whenever possible. Issue(s) and associated requested revision(s) should be clearly stated, and specific reference should be made to the section of the document to which they apply (i.e., line number, section title, or page number).
- We will only consider feedback from individuals or groups who identify themselves. If multiple individuals or teams wish to submit feedback, please consolidate them into a single response. Only 1 response per organization will be considered.
- Comments should be restricted to the content of the draft document and should not contain any language that could be considered disrespectful or inflammatory.
- The CDA-AMC may use your submitted feedback in documents that will become available to the public. The confidentiality of any submitted information cannot be protected. CDA-AMC does not provide direct responses to feedback received.
- There is no limit on the number of pages that may be submitted if needed. Use a minimum 11-point font on 8.5″ by 11″ page